| Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study |
|
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Safety and efficacy of danicopan in patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis |
|
Expert Review of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial |
|
Lancet Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial |
|
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
| Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome |
|
Journal of Pediatric Hematology/Oncology |
Aplastic Anemia |
| Romiplostim for aplastic anemia: beyond an eltrombopag alternative. |
|
Haematologica |
Aplastic Anemia |
| Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review |
|
Experimental Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
| RNA splicing as a therapeutic target in myelodysplastic syndromes |
|
Seminars in Hematology |
Myelodysplastic Syndromes (MDS) |
| Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) |
|
Cancers |
Chronic Myelomonocytic Leukaemia (CMML), Myelodysplastic Syndromes (MDS) |
| Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS) |
|
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
